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Summary
Background Melanoma incidence is rising rapidly worldwide among white popula-
tions. Defining higher-risk populations using risk prediction models may help
targeted screening and early detection approaches.
Objectives To assess the feasibility of identifying people at higher risk of melanoma
using the Williams self-assessed clinical risk estimation model in U.K. primary care.
Methods We recruited participants from the waiting rooms of 22 general practices
covering a total population of > 240 000 in three U.K. regions: Eastern England,
North East Scotland and North Wales. Participants completed an electronic ques-
tionnaire using tablet computers. The main outcome was the mean melanoma
risk score using the Williams melanoma risk model.
Results Of 9004 people approached, 7742 (86%) completed the electronic ques-
tionnaire. The mean melanoma risk score for the 7566 eligible participants was
1715  851, with small regional differences [lower in England compared with
Scotland (P = 0001) and Wales (P < 0001), mainly due to greater freckling
and childhood sunburn among Scottish and Welsh participants]. After weighting
to the age and sex distribution, different potential cut-offs would allow between
4% and 20% of the population to be identified as higher risk, and those groups
would contain 30% and 60%, respectively of those likely to develop melanoma.
Conclusions Collecting data on the melanoma risk profile of the general population
in U.K. primary care is both feasible and acceptable for patients in a general prac-
tice setting, and provides opportunities for new methods of real-time risk assess-
ment and risk stratified cancer interventions.
What’s already known about this topic?
• Programmes to identify people at higher risk of melanoma and offer them preven-
tive advice about sun protection, skin awareness, early consultation or surveillance
are of increasing interest to healthcare providers in the U.K. and internationally.
• Numerous models exist for predicting future risk of melanoma, with little differ-
ence between models suitable for self-assessment and those requiring a healthcare
professional; none has been calibrated for the U.K. population.
What does this study add?
• Collecting data on the melanoma risk profile of the general population in U.K. pri-
mary care is both feasible and acceptable.
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• This provides an opportunity for new methods of real-time risk assessment in pri-
mary care.
• Using the Williams model produces a distribution of risk in the population attend-
ing general practices that allows identification of subgroups at different levels of
risk.
• As regional differences were small, a single approach could be implemented.
Melanoma is the leading cause of skin cancer deaths in the
U.K., with incidence rates having increased between 2000 and
2009 by 55% and continuing to rise.1,2 Identifying people at
higher risk of melanoma can help early diagnosis and preven-
tion, and in turn mortality.3,4 Screening programmes to iden-
tify those at higher risk of melanoma and offer them
preventive advice about sun protection and skin awareness
and early consultation or surveillance are, therefore, of
increasing interest to policy and healthcare providers.
Currently, mass screening is not recommended in the U.K.
because of difficulties in identifying the target population,5 as
well as due to concerns about the low incidence of melanoma
and therefore the time and resources required to identify a
relatively small number of people with the disease.6 Addition-
ally, while the SCREEN project in northern Germany has sug-
gested that population screening is feasible and may have an
impact on diagnosis and 5-year mortality, it led to an increase
in biopsies,7,8 and there has been insufficient evidence for the
cost-effectiveness of routine screening of the general popula-
tion using a total body skin examination.9 Previous studies,
however, suggest that selective, targeted screening might be
more cost-effective as the cost falls dramatically when screen-
ing is targeted to higher-risk populations, defined variously by
age, family history or phenotypic characteristics.10–14 A strati-
fied approach is currently recommended for Australian pri-
mary care physicians, who are advised to perform skin
examinations every 3–12 months in people who have multiple
atypical or dysplastic naevi or a first-degree relative with mela-
noma.15
The overall impact of stratified screening for melanoma,
however, depends on easily and accurately identifying a high-
risk group.16 Such identification may be improved by the use
of risk prediction models. Our recent systematic review identi-
fied 25 risk models for predicting future risk of melanoma.17
Twelve of those are suitable for self-assessment (defined as
not including any of the following factors: dysplastic or atypi-
cal naevi, actinic lentigines, total body naevus count, genetic
analysis requiring samples, or specialized equipment such as
dermoscopy or colorimetry). Many had performance measures
comparable with those for other cancers, including breast can-
cer18 and colon cancer,19 and there was little difference
between those scores suitable for self-assessment and those
requiring a healthcare professional. The review did not iden-
tify any risk models calibrated for the U.K. population and
none was more than moderately predictive. Of those suitable
for self-assessment, only one, developed from a U.S. case–con-
trol study by Williams et al.,20 had been validated outside the
development population. It is a self-assessed clinical risk esti-
mation model not requiring full-body skin examination that,
in a validation population, had an area under the receiver
operator characteristic curve of 070 [95% confidence interval
(CI) 064–077] and was able to identify 15% of the popula-
tion in whom 50% of melanomas would be expected to
develop. The Williams score can therefore be used to deter-
mine population risk of melanoma and enable stratified
screening based on individual risk. The aim of this study was
to assess the feasibility of identifying people at higher risk of
melanoma using the Williams self-assessed clinical risk estima-
tion model, the ‘Williams model’20 in U.K. primary care.
Methods
Study population and data collection
Ethical approval was gained from the West Midlands Research
Ethics Committee (13/WM/0405). Participants were recruited
from general practices in Eastern England (n = 10), North East
Scotland (n = 6) and North Wales (n = 6) between February
2014 and March 2015. Patients and companions aged
≥ 20 years were approached in general practice waiting rooms
by trained researchers at different times of day and different
days of the week; posters were also placed in the waiting
rooms to advertise the study. Those willing to take part were
invited to complete an electronic questionnaire using tablet
computers. The sex and reason for not wishing to participate
was recorded for each person choosing not to take part.
Tablet computer-administered electronic questionnaire
The electronic questionnaire consisted of two sections: the
Williams model and additional demographic variables. The
questions for the Williams model were phrased as originally
reported20 and included: sex, age, natural hair colour at the
age of 15 years, number of raised moles on both arms, den-
sity of freckles on both arms before the age of 20 years, num-
ber of severe sunburns up to the age of 18 years and prior
nonmelanoma skin cancer (basal cell cancer and squamous cell
cancer). Participants were also asked whether they had had
melanoma. Age was collected in six age bands (20–34, 35–
44, 45–54, 55–64, 65–74 and ≥ 75 years). The questions and
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possible responses for the other risk factors are shown in
Table 1. Photographic images were included of raised moles
and freckles alongside those questions to facilitate completion
of the questionnaire by each participant independently. The
demographic section included questions on ethnic group, edu-
cation level and employment status.
Statistical analyses
The risk score for each participant was calculated using the
points scoring system developed by Williams et al.20 We then
computed the mean risk score and standard deviation for the
entire sample and for each of the three regions separately,
and compared the mean risk in each of the three regions
using linear regression adjusting for the age and sex of par-
ticipants. We proceeded to calculate the proportion of partic-
ipants who would be identified as high risk using each of
the four risk score cut-offs used by Williams et al.:20 25, 28,
30 and 34. We repeated this, weighted to the age and sex
distribution of the registered practice populations, to obtain
estimates of the proportion of the population who would be
classified as high risk if the entire practice population had
been questioned. To estimate the positive predictive value
(PPV) and negative predictive value (NPV) for each cut-off
we assumed that the Williams model would perform equally
in the U.K. population as in the published validation study.
We used the sensitivity and specificity reported by Williams
et al. for each of the four risk score cut-offs and the pub-
lished national data for 2011 crude melanoma incidence to
estimate 5-year PPVs and 5-year NPVs. All analyses were per-
formed using Stata version 12 (StataCorp, College Station,
TX, U.S.A.).
Results
General practices
The 10 Eastern England practices had between 4229 and
20 279 registered patients and covered a total population of
112 651 patients; most were urban (n = 7). The six in North
East Scotland were mostly rural or semirural (n = 5) with
between 1845 and 20 976 registered patients covering a total
population of 68 010, and the six in North Wales were
mostly urban or semiurban (n = 5) with between 5801 and
15 409 registered patients covering a total population of
60 096 (Table 2).
Participant recruitment
The total person-time spent recruiting was 1009 h, with
the time in each practice ranging from 15 to 93 h and the
mean time per participant ranging from 21 to 185 min
(mean 82  50). This variation was largely due to differ-
ences in patient flow within practices. Factors facilitating
quicker recruitment included: larger practice size; a greater
number of doctors in the practice at the time; larger wait-
ing rooms with more space to approach patients; and
longer waiting times for appointments. Conversely, recruit-
ment was difficult at times when large numbers of patients
were arriving for very short appointments, such as blood
tests or flu vaccinations, as many were called in before they
had time to complete the questionnaire. Overall, 9004 peo-
ple (37% of the registered population) were approached
and 7742 completed the electronic questionnaire (86%)
(Fig. 1); 275 people agreed to take part but were called for
their appointment before completing the electronic question-
naire (3%), and 1063 people (12%) declined to participate.
The total number recruited from the Eastern England prac-
tices was higher than in North East Scotland or North
Wales (4140 compared with 1509 and 2093, respectively)
but acceptance rates were similar in all three regions (East-
ern England 853%, North East Scotland 868%, North
Wales 867%). Reasons for not wishing to participate var-
ied: over half either provided no reason or indicated no
interest in the study (n = 593, 558%) with other common
reasons including poor English (n = 86, 81%), no time
(n = 72, 68%), and not having glasses with them (n = 59,
56%).
Table 1 Williams model melanoma risk score calculation (range
0–67)20
Risk factor Score
Sex
Male 7
Female 0
Age (years)
35–44 0
45–54 5
55–64 8
65–74 11
Natural hair colour at age 15 years
Dark brown/black 0
Light brown 4
Blond 5
Red 8
Number of severe sunburns aged 2–18 years
None 0
1–4 1
5–9 4
10 or more 7
Prior nonmelanoma skin cancer
No 0
Yes 13
Number of raised moles on both arms
None 0
1 3
2 5
3 or more 11
Density of freckles on arms before age 20 years
None 0
A few 4
Several 6
A lot 10
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Participants
We excluded 177 (23%) participants (Eastern England 100, North
East Scotland 29, North Wales 47) who had a history of mela-
noma. Therefore, 7566 participants are included in further analy-
ses. Table 3 shows the details of these 7566 participants by the
three regions, with comparison where possible to the total patients
registered in the practices. The majority were white (British and
others, 965%), reflecting the regional populations.21,22 Our sam-
ple contained proportionately fewer male and older participants
than that of registered patients in the practices. Most were retired
(301%) or working full time (359%), and education levels were
similar to those in the 2011 Office of National Statistics, with over
a quarter having an undergraduate degree (104%), or postgradu-
ate degree or professional qualification (167%).
Distribution of melanoma risk factors and scores
Table 4 shows the mean risk score in each of the three
regions and for the entire study population along with a
breakdown of the proportion with each risk factor. The mean
risk score for all 7566 participants was 1715  851 and was
similar in each of the three regions (Eastern England: mean
1679  847; North East Scotland: mean 1787  841;
North Wales: mean 1737  860). This difference in mean
scores between North East Scotland and Eastern England of
110 (95% CI 059–161) reduced to 067 (95% CI 026–
109, P = 0001) after adjusting for age and sex; the corre-
sponding difference between North Wales and Eastern England
increased from 060 (95% CI 014–105) to 080 (95% CI
043–118, P < 0001) after adjusting for age and sex. These
differences were mostly explained by increased density of
freckles on both arms before the age of 20 years and a greater
number of severe sunburns aged 2–18 years reported by par-
ticipants in both North East Scotland and North Wales; the
difference between North East Scotland and North Wales was
not significant (P = 058).
Figure 2 shows the distribution (unweighted) of mela-
noma risk scores in each of the three regions and the entire
study population, overlaid with the four cut-off points used
in the Williams model. Table 5 shows the percentage of
study participants above each of the four cut-off points used
in the Williams model, along with the estimated percentage
of the registered practice population at all the included prac-
tices (estimated by weighting to age and sex distribution of
practice populations) above each cut-off. Estimated PPVs and
NPVs are also given for each cut-off in the three regions
using the values for the relative risk, sensitivity and speci-
ficity reported in the Williams paper and assuming that the
model is transferable to the U.K. population.20 These suggest
that, for example, using the lowest cut-off of 25 would clas-
sify approximately 177% of the practice populations in East-
ern England as higher risk. This group would contain
approximately 61% of the people predicted to be diagnosed
with a melanoma at any time in the future and approxi-
mately 31% of this group would be expected to develop
melanoma in the following 5 years. These values are similar
for Northeast Scotland and North Wales but a slightly greater
proportion of the population would be classified as high risk
in both regions than in Eastern England at all thresholds
(Table 5).
Discussion
To our knowledge this is the first study to use tablet comput-
ers to collect data specifically on risk of cancer in primary
care. We have shown that collecting data on the risk profile of
the general population in U.K. primary care is both feasible
and acceptable. This provides an opportunity for new methods
of real-time risk assessment in primary care for melanoma and
for other cancers. We have also shown that using the Williams
model20 produces a distribution of risk in the population
attending general practices that allows identification of sub-
groups at different levels of risk. Although this distribution
varied slightly between the three U.K. regions included in this
study, the differences were small and, from a policy
Table 2 Characteristics of general practices
Practice
type
Practice
populationa
Cancer
prevalenceb
Deprivation
(IMD
quintile)c
Number
recruited
Eastern England
Urban 20 279 21 3 422
Urban 17 657 28 2 392
Urban 11 396 30 3 395
Rural 11 129 21 1 436
Rural 10 517 18 1 300
Rural 10 408 21 2 396
Urban 9549 22 1 433
Urban 9115 22 2 458
Urban 8372 24 3 396
Urban 4229 27 4 409
North East Scotland
Semirural 20 976 21 2 431
Semirural 15 726 22 3 326
Semirural 12 222 28 1 150
Urban 11 062 19 5 368
Rural 6179 24 2 122
Rural 1845 16 1 83
North Wales
Semiurban 15 409 24 2 387
Urban 13 068 24 3 384
Urban 9935 28 4 195
Rural 8331 28 2 502
Semiurban 7552 06 4 236
Semiurban 5801 22 2 342
aAt time of recruitment. bPrevalence data in the Quality and Out-
comes Framework: percentage of patients with a diagnosis of
cancer, excluding nonmelanotic skin cancer. England and Wales
2013–201434 and Scotland 2012–2013.35 cIndex of Multiple
Deprivation (IMD) quintiles computed using the practice post-
code and published values for IMD where 1 is the least
deprived.
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perspective, suggest that a single risk stratifying approach
could be implemented across the whole U.K. in the future.
The main strength of this study is the method of collecting
data. Almost 90% of patients approached while attending rou-
tine general practice agreed to take part, and we were able to
easily recruit 7742 participants from three regions across the
U.K. with an average total researcher time per participant of
< 10 min. Furthermore, we were able to collect data from a
large sample representing a general practice population of
almost a quarter of a million people, and drawn from three
distinct regions across the U.K.
This data collection method, however, has its limitations.
Firstly, the recruited sample is drawn from those attending
general practice, so we acknowledge that we may not have
accessed individuals who are reluctant to visit their doctors,
and that some selective approaching of potential participants
was inevitable. Older people and women will tend to be over-
represented as they attend general practice more often than
younger people and men;23 women are also more likely to be
in the practice accompanying young children or more elderly
people. To account for this we repeated our analysis with our
sample weighted to the practice-registered populations. This
requires the assumption that the risk of developing melanoma
in the patients not attending the practice is the same as those
of the same age and sex who did attend the practice during
the recruitment period. We think this assumption is reason-
able as most primary care consultations are not related to mel-
anoma or its risk factors. Our sample is also predominantly
white (British and others), which limits the generalizability of
our findings to other ethnic groups, many of whom would be
at lower risk of melanoma. The ethnic distribution of our
sample does, however, reflect the regional populations in the
three areas, where over 90% are white British, and are likely
to be targeted in a risk-stratified melanoma screening pro-
gramme.
Other limitations include that this was a cross-sectional
study with no follow-up. The absence of melanoma outcomes
means we are unable to assess the performance of the Wil-
liams model in this U.K. population. The estimated 5-year
PPVs and NPVs are therefore based on the sensitivity and
specificity of the different risk score cut-off values reported
from the original paper by Williams et al.20 We acknowledge
that the model was self-validated on a fairly small dataset from
Washington State, U.S.A., where the cases were all white and
aged between 35 and 74. The performance measures reported
by Williams et al. at the different thresholds are, therefore,
estimates calculated from this sample and not the whole popu-
lation. The model has also not been calibrated for the U.K.
population. The age-standardized incidence of melanoma is
lower in the U.K. than in the U.S.A. (173 per 100 000 for
England in 2011,6 compared with 229 per 100 000 in the
U.S.A. in 201124), so the sensitivity may be slightly higher
and the specificity slightly lower due to spectrum effect. We
also excluded patients with previous melanoma, while national
incidence data include all new cases of melanoma. The Wil-
liams model does not contain some expected risk factors such
as family history of skin cancer and skin colour. Our review
found that family history was absent in many models: it was
considered in 18 of the models but only remained in the final
score in six.17 Finally, most of the questions were asking
either about the past and so subject to recall bias, or required
participants to count raised moles. However, the same biases
Fig 1. Recruitment flowchart.
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would be true for the original Williams model, which per-
formed well in an external validation cohort and in this study
we additionally included photographs of moles and freckles to
help participants distinguish between them, which, if any-
thing, would be expected to improve the performance of the
model.
Only one similar study has been conducted for melanoma
risk,25 where patients at 16 English general practices com-
pleted a paper questionnaire based on a risk score developed
by Mackie.26 While this is, therefore, the first study to use
tablet computers to collect melanoma or any other cancer-spe-
cific risk factor information in general practice waiting rooms,
tablet computers have been used in this setting previously.
One collected general health risk information from patients
attending an Aboriginal Community Controlled Health Service
in Australia,27 and two U.K. vignette-based studies have
recently investigated ethnic differences in preferences for pros-
tate cancer investigation,28 and for investigation for possible
lung, colorectal and pancreatic cancer:29 both had high
(> 70%) recruitment rates. This study therefore supports the
increasing interest in making the most of the ‘waiting room
wait’, both for clinical practice and research. It also identifies
a number of factors to be considered when recruiting partici-
pants from primary care waiting rooms, in particular the need
to consider the layout of the waiting room and patient flow
through each practice and, where possible, select times when
there are more appointments with general practitioners and
fewer for very short consultations such as blood tests or flu
vaccinations. However, as we did in this study, it remains
important to sample at different times during the day to pro-
vide the opportunity to recruit a range of patient groups. For
example, working individuals may favour early and late
Table 3 Sociodemographic characteristics of participants
Characteristic
Eastern England,
n (%)
North East Scotland,
n (%)
North Wales,
n (%)
Total,
n (%)
Population > 20 years
registered at all
practices, n (%)
Sex
Male 1399 (346) 517 (349) 775 (379) 2691 (356) 91 593 (495)
Female 2641 (654) 963 (651) 1271 (621) 4875 (644) 93 560 (505)
Age (years)
20–35 916 (227) 298 (201) 567 (277) 1781 (235) 43 286 (234)
35–44 692 (171) 218 (147) 335 (164) 1245 (165) 32 500 (175)
45–54 671 (166) 238 (161) 351 (172) 1260 (167) 35 804 (193)
55–64 611 (151) 264 (178) 325 (159) 1200 (159) 29 245 (158)
65–74 630 (156) 260 (176) 317 (155) 1207 (160) 24 374 (132)
≥ 75 520 (129) 202 (136) 151 (74) 873 (115) 19 944 (108)
Ethnic group
White British 3620 (896) 1372 (927) 1945 (951) 6937 (917) –
White other 224 (55) 75 (51) 63 (31) 362 (48) –
Mixed 27 (07) 9 (61) 5 (02) 41 (05) –
Asian or Asian British 87 (22) 9 (61) 12 (06) 108 (14) –
Black or black British 35 (09) 5 (03) 7 (03) 47 (06) –
Chinese 12 (03) 2 (01) 5 (02) 19 (03) –
Other ethnic group 35 (09) 8 (05) 9 (04) 52 (07) –
Education
None 719 (178) 295 (199) 349 (171) 1363 (180) –
GCSE, O-level or CSE 975 (241) 285 (192) 528 (258) 1788 (236) –
Vocational 684 (169) 293 (198) 387 (189) 1364 (180) –
A-level or equivalent 570 (141) 162 (109) 271 (132) 1003 (133) –
Undergraduate degree 386 (96) 190 (128) 210 (103) 786 (104) –
Postgraduate degree or
professional qualification
706 (175) 255 (172) 301 (147) 1262 (167) –
Employment status
Retired 1276 (316) 481 (325) 517 (253) 2274 (301) –
Unemployed, seeking work 99 (25) 29 (20) 63 (31) 191 (25) –
Unemployed, unable to work 63 (16) 23 (16) 72 (35) 158 (21) –
Student 67 (17) 54 (36) 64 (31) 185 (24) –
Working part time 778 (193) 288 (195) 331 (162) 1397 (185) –
Working full time 1393 (345) 472 (319) 849 (415) 2714 (359) –
Home carer/homemaker 308 (76) 97 (66) 100 (49) 505 (67) –
Permanently sick or disabled 56 (13) 36 (24) 50 (24) 142 (19) –
GCSE, General Certificate of Secondary Education; CSE, Certificate of Secondary Education.
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Table 4 Risk factor profile of participants
Risk factor Point score Eastern England, n (%) North East Scotland, n (%) North Wales, n (%) All, n (%)
Sex
Male 7 1399 (346) 517 (349) 775 (379) 2691 (356)
Female 0 2641 (654) 963 (651) 1271 (621) 4875 (644)
Age (years)
< 44 0 1608 (398) 516 (349) 902 (440) 3026 (400)
45–54 5 671 (166) 238 (161) 351 (172) 1260 (167)
55–64 8 611 (151) 264 (178) 325 (159) 1200 (159)
≥ 65 11 1150 (285) 462 (312) 468 (229) 2080 (275)
Natural hair colour at age 15 years
Dark brown/black 0 1518 (376) 579 (391) 811 (396) 2908 (384)
Light brown 4 1634 (404) 574 (388) 830 (406) 3038 (402)
Blond 5 718 (178) 230 (155) 306 (150) 1254 (166)
Red 8 170 (42) 97 (66) 99 (48) 366 (48)
Number of severe sunburns aged 2–18 years
None 0 2111 (522) 698 (472) 892 (436) 3701 (489)
1–4 1 1623 (402) 609 (411) 964 (471) 3196 (422)
5–9 4 197 (49) 94 (64) 121 (59) 412 (54)
10 or more 7 109 (27) 79 (53) 69 (34) 257 (34)
Prior nonmelanoma skin cancer
No 0 3930 (973) 1457 (984) 1996 (976) 7383 (976)
Yes 13 110 (27) 23 (16) 50 (24) 183 (24)
Number of raised moles on both arms
None 0 2654 (657) 1020 (689) 1298 (634) 4972 (657)
1 3 618 (153) 163 (110) 279 (136) 1060 (140)
2 5 312 (77) 123 (83) 202 (99) 637 (84)
3 or more 11 456 (113) 174 (118) 267 (131) 897 (119)
Density of freckles on arms before age 20 years
None 0 1793 (444) 591 (400) 707 (346) 3091 (409)
A few 4 1309 (324) 481 (325) 792 (387) 2582 (341)
Several 6 518 (128) 159 (107) 261 (128) 938 (124)
A lot 10 420 (104) 249 (168) 286 (140) 955 (126)
Total score: mean (SD) 168 (85) 179 (84) 174 (86) 171 (85)
Fig 2. Distribution of risk scores. Vertical
lines mark the four different score cut-offs
(25, 28, 30 and 34) of the Williams model20
melanoma risk score with the percentage of
participants above each threshold alongside.
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appointments, older patients may favour appointments in the
middle of the day and parents with children may favour after
school appointments.
This study also provides useful evidence for the planning
and development of future screening and educational pro-
grammes in the U.K. for people at higher risk of melanoma. It
shows that collecting information on risk factors in general
practices across the U.K. is feasible and acceptable to patients,
and that use of a melanoma risk model allows stratification of
the population into different risk groups. The small differences
in risk profiles between the three U.K. regions are also consis-
tent with U.K. melanoma incidence rates, which show only
small and nonstatistically significant differences,30 and suggest
that a single approach could be introduced across the U.K.
Identifying those at higher risk in this way, therefore, could
allow screening, surveillance or education programmes to be
targeted at those most likely to benefit, including specific
advice and support via primary care. In particular, the risk
stratification could be used to determine the interval for
surveillance, with those at higher risk being recommended to
have more frequent screening. This is of particular relevance
to conditions like melanoma where the overall incidence is
low but the benefits of prevention or identifying people with
disease earlier are substantial. The low incidence means inter-
ventions at the whole population level have considerable
implications in terms of healthcare costs to benefit only a
small number for whom early detection could improve treat-
ment options, reduce morbidity and mortality, and both phys-
ical and psychological consequences to the large numbers who
are unlikely to ever develop the condition.31
The proportion of the population in the higher-risk group
depends on the choice of risk cut-off point. As with all screen-
ing there is a trade-off between sensitivity and specificity. A
cut-off with higher sensitivity will increase the proportion of
those likely to go on to develop melanoma being identified as
higher risk, but at the expense of a lower specificity and a lar-
ger proportion of the population classified as higher risk.
Using the four cut-off points of the Williams model in this
study would identify between 4% and 20% of the population
as candidates for a targeted intervention, and those groups
would contain between approximately 30% and 60% respec-
tively, of those likely to develop melanoma. This is not dis-
similar to the 87% of the population identified as ‘worryingly
high risk’ or ‘very increased risk’ in the study by Jackson
et al.25 While such strategies are likely to increase local referral
rates and dermatology workload, and there is a U.K. shortage
Table 5 The population above various risk score cut-offs of the Williams model melanoma risk score20 along with the estimated positive
predictive values (PPVs) and negative predictive values (NPVs)
Region
Williams risk
score cut-off
Sample above
cut-off (%)
Practice population
above cut-off (%)a
Estimated 5-year
PPV (%)b
Estimated 5-year
NPV (%)c
Eastern England 25 165 177 31 995
28 103 110 34 994
30 74 79 43 993
34 31 35 57 992
North East Scotland 25 208 224 34 994
28 127 129 37 993
30 96 98 47 993
34 32 36 62 991
North Wales 25 185 193 37 994
28 113 122 39 993
30 81 85 48 992
34 37 49 63 991
All 25 179 194 – –
28 110 118 – –
30 80 86 – –
34 33 39 – –
aWeighted for the age and sex of the registered population in each participating practice. bEstimated 5-year PPV: the estimated proportion of
the population considered higher risk who would be diagnosed with melanoma in the next 5 years, assuming the same performance of the
Williams model as reported in Williams et al. 2011 and a prevalence of newly diagnosed cases of 1045 per 100 000 for England (the 2011
crude incidence of melanoma in England from data from the Office of National Statistics multiplied by 5), 119 per 100 000 for Wales (the
2011 crude incidence of melanoma in Wales from the Welsh Cancer Intelligence and Surveillance Unit) and 1145 per 100 000 for Scotland
(the 2011 crude incidence of melanoma in Scotland from the Cancer Information Programme, Information Services Division Scotland). cEsti-
mated 5-year NPV – the estimated proportion of the population considered low risk who would not be diagnosed with melanoma in the
next 5 years, assuming the same performance of the Williams model as reported in Williams et al.20 and a prevalence of newly diagnosed
cases of 1045 per 100 000 for England (the 2011 crude incidence of melanoma in England from data from the Office of National Statistics
multiplied by 5), 119 per 100 000 for Wales (the 2011 crude of melanoma in Wales from the Welsh Cancer Intelligence and Surveillance
Unit) and 1145 per 100 000 for Scotland (the 2011 crude incidence of melanoma in Scotland from the Cancer Information Programme,
Information Services Division Scotland).
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of dermatologists, a recent review suggests that melanoma
early detection programmes might be cost-effective14 if tar-
geted at high-risk populations such as older men32 or those
with a family history of melanoma.12 It is likely that identify-
ing higher-risk individuals using a risk score would be more
cost-effective, but further studies are needed to confirm this
and to determine the most cost-effective intervals for surveil-
lance amongst those at different levels of risk.
The finding that collecting risk information in waiting
rooms in general practices across the U.K. using tablet com-
puters was both feasible and acceptable to patients also has
implications beyond screening for melanoma. In addition to
completing risk assessment questionnaires, patients could also:
identify consultation goals and enable doctors to better tailor
appointments; be provided with educational material; and
complete decision aids.33 The acceptability of a self-completed
tool also suggests that similar approaches could be used more
widely in settings outside the waiting room, such as in phar-
macies or secondary care, as well as potentially via web-based
applications.
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